How effective is pembrolizumab in cisplatin-ineligible bladder cancer? Results from KEYNOTE-052
Understanding resistance to combined BRAF and MEK inhibiton in melanoma and the significance of CDK4
Melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better PFS
Sharing routine patient data between GPs and hospitals
Metastatic colorectal cancer: trifluridine/ tiripacil or regorafenib?